Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
US-2017217903-A1 · Aug 3, 2017 · US
Methods and compositions for the treatment of cancer cachexia
US11529323B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11529323-B2 |
| Application number | US-201816646424-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 13, 2018 |
| Priority date | Sep 13, 2017 |
| Publication date | Dec 20, 2022 |
| Grant date | Dec 20, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating cancer cachexia in a subject, comprising administering to the subject a therapeutically effective amount of AR-42, having the following chemical structure: and GTx-024, having the following chemical structure: 2. The method of claim 1 , wherein the subject has been diagnosed as having cancer cachexia.
Assignees
Inventors
Classifications
having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol · CPC title
- A61K31/167Primary
having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Anabolic agents (androgens A61P5/26) · CPC title
Drugs for disorders of the muscular or neuromuscular system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11529323B2 cover?
- In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as h…
- Who is the assignee on this patent?
- Ohio State Innovation Foundation
- What technology area does this patent fall under?
- Primary CPC classification A61K31/167. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).